CENTERS OF CLINICAL RESEARCH EXCELLENCE AT RCMI ELIGIBLE INSTITUTIONS WITH MEDICAL SCHOOLS Release Date: January 20, 1999 RFA: RR-99-005 (see NOT-RR-04-003) P.T. National Center for Research Resources Application Receipt Date: March 11, 1999 PURPOSE The National Center for Research Resources (NCRR) invites applications for the establishment of Centers of Clinical Research Excellence (CCRE) at NCRR-supported Research Centers in Minority Institutions (RCMI) with affiliated medical schools. The purpose of this Request for Applications (RFA) is to augment and strengthen the institutional clinical research capabilities. This will be done by providing support to recruit senior basic or clinical research investigators, who are established investigators with independent research support. They can serve as mentors to more junior investigators and for those in junior career development in clinical research. These new faculty will receive support to establish their research laboratories, acquire specialized equipment, and support postdoctoral fellows and technical assistants. It is anticipated that they will serve as magnet investigators for the recruitment of other research faculty who will compliment the specific research area. Ideally, this research area will focus on one or more of the diseases that disproportionately affect the indigenous populations served by the RCMI institution. Long-range, it is anticipated that this will facilitate the development of the institution's clinical research capacity. It is also anticipated that the CCRE will compliment the RCMI Clinical Research Infrastructure Initiative (RCRII) that began with the first awards in FY 1995. The National Institutes of Health (NIH) recognizes that minority institutions are an integral component of our national biomedical research agenda. Therefore, the NIH is offering programmatic assistance for the development of the technology and resources that are necessary to conduct state-of-the-art clinical research at these institutions. Long-range, it is anticipated that this will facilitate the participation of these institutions in preparing the next generation of clinical investigators. This RFA is one way that the NIH identifies and supports clinical investigators at eligible institutions to conduct and report the meritorious, preliminary research that will foster successful competition for traditional research project grants (e.g., R-series and P-series) during the performance period of the award. Beyond this, as is the case for the RCRII, the penultimate objectives of this initiative are: (1) assist the participating institutions to conduct clinical research which will improve the health of the Nation's citizens, especially racial and ethnic minorities; (2) enhance the clinical research capacity of the eligible institutions; and (3) position these medical schools to compete successfully for clinical research support. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. Potential applicants may obtain a copy of "Healthy People 2000" at http://www.crisny.org/health/us/health7.html. ELIGIBILITY REQUIREMENTS Applications will only be accepted from domestic, public or private, non-profit, academic institutions that award the M.D. degree, at which more than 50 percent of the students enrolled are from cultural or racial minority groups. Each applicant institution MUST identify a collaborating institution. All collaborating institutions must be domestic Federal or non-Federal, public or private, non-profit organizations. This will facilitate additional mentoring and research collaboration. The principal investigator, who serves as CCRE Program Director, must be a U.S. citizen, permanent resident, or non-citizen national. An award pursuant to this RFA will not be made until and unless the institution has appointed a Program Director who is an established clinical investigator with an active research program that is supported by extramural investigator-initiated clinical research support and who has the professional skills needed to direct the Program. Participating applicant investigators who are already resident at the applicant institution must have completed two or more years of postdoctoral clinical research and must be full-time employees of the applicant institution. Any collaborating investigator must be an NIH grantee currently supported by R-series and/or P-series. MECHANISM OF SUPPORT The Cooperative Agreement (U-series) award is the administrative mechanism for supporting activities in which the NIH collaborates substantially in scientific and/or programmatic matters with the awardee institution(s). The Specialized Center-Cooperative Agreement (U54) mechanism will be used to support the CCRE award. It is anticipated that collaborating scientists will benefit from a broader range of research resources and interdisciplinary research approaches than are available at any one institution. A CCRE award will support research and research development activities within the scope of the program priorities identified by the NCRR. The NIH will support and stimulate the activities of the awardee(s) by working as a partner. The NIH will not assume direction, take primary responsibility, or in any other way dominate the activity. The section TERMS AND CONDITIONS contains detailed descriptions of the responsibilities, relationships, and governance of the activities supported by the cooperative agreements for the Centers for Clinical Research Excellence. FUNDS AVAILABLE The NCRR plans to make up to three awards in Fiscal Year 1999. An applicant may request support for up to five years and a direct cost budget of up to $1 million per year, excluding indirect costs on consortium arrangements. Because the nature and scope of the research proposed may vary, it is anticipated that the size of each award will also vary. Although the NCRR financial plans provide support for this program, awards pursuant to this RFA are contingent upon the availability of funds and the receipt of applications of outstanding scientific and technical merit. At this time, it is not known if competing renewal applications will be accepted and/or if this RFA will be reissued. Applicants planning to respond to this RFA by submitting an application for the CCRE that requests $500,000 or more in direct costs for any year are advised that he or she must contact the Director, Research Infrastructure (DRI), NCRR before submitting the application, i.e., as plans for the study are being developed. Furthermore, the applicant must obtain agreement from the DRI that the application will be accepted for consideration for award. Finally, the applicant must identify, in a cover letter sent with the application, the staff member in the Center who agreed to accept assignment of the application. RESEARCH OBJECTIVES Background The NCRR intends to foster an improved health status of and eliminate the health care disparity experienced by racial and ethnic minority Americans. Focused research and research career development programs such as the CCRE are used to achieve this objective. Secondly, the NIH recognizes that the contributions that minority academic health centers can make to fulfilling the promise of the NIH research agenda are unique and essential. Therefore, the NIH has the responsibility to the Nation to ensure that these institutions can develop the technology and other resources needed to conduct state-of-the-art clinical research. Thirdly, the NIH, by means of the CCRE and other programs, can foster the collaborative research affiliations needed to address clinical research problems relevant to the communities and regions served by the CCRE grantee. The CCRE's objectives will be accomplished by providing support to recruit magnet clinical investigators and providing support for developmental clinical research projects. With respect to the former, the magnet investigator(s) will increase the institution's clinical research milieu and will also serve as mentors for more junior investigators at the institution. The developmental projects will allow clinical research faculty at the institution to use their research skills and abilities to obtain preliminary data and publications that can help ensure successful competition for traditional research project grants during the performance period of the award. Research Areas In FY 1985, the legislation which authorized the RCMI Program called attention to the disparity in the health status of minorities as compared to white Americans. More recently, President Clinton called these disparities to the Nation's attention in his FY1999 budget proposal for the Department of Health and Human Services. He called for initiatives to eliminate gaps between the health of non-Latino whites and minorities by the year 2010. The President declared that such disparities, as seen for a variety of cancers (breast, prostate and colon/rectal), diabetes, infant mortality, cerebrovascular and cardiovascular disease, and AIDS "are unacceptable in a country that values equality and equal opportunity." The CCRE initiative is consistent with and in response to this mandate. The research plan of an application for a CCRE award must contain the description of up to three multi disciplinary, collaborative, developmental research projects that will be mutually beneficial to participating investigators through coordinated, cooperative interactions. The research excellence of these projects will be enhanced by effectively using the scientific and technical strengths of collaborating investigators. These projects must add to the body of clinical research that is the overall focus of the CCRE. SPECIAL REQUIREMENTS The awardee will work to establish research priorities within the approved research scope of each CCRE award through discussions with the DRI. The NCRR reserves the right to include outside consultants/experts in these discussions. After the awardee and the DRI have set the priorities, the awardee will be responsible for conducting the research activities. The awardee and the DRI will interact in a cooperative manner throughout the duration of the award to facilitate progress and resolve any problems that may arise. Other NIH program staff may participate in establishing research priorities throughout the performance period of the CCRE award. TERMS AND CONDITIONS The following Terms of Award are in addition to, and not instead of, otherwise applicable OMB administrative guidelines, DHHS Grant Administration Regulations at 45 CFR Part 74 and 92, and other DHHS, PHS, and NIH grant administration policies. Cooperative Agreements are subject to the administrative requirements outlined in pertinent OMB, DHHS, PHS, and NIH guidelines, with particular emphasis on DHHS regulations at 42 CFR Part 52 and 45 CFR Part 74. Indirect costs are calculated and awarded for cooperative agreement awards the same as for grants. 1. The Awardee Rights and Responsibilities o The awardee has primary authority and responsibility to define the scientific objectives and approaches, and to plan, conduct, analyze, and publish results, interpretations, and conclusions of the studies; o The awardee has the primary responsibility for establishing effective and substantial research collaborations with NIH grantees. The scope and nature of research on common protocols must be adequately documented and must ensure participation, collaboration, and sharing of methods and data among collaborating organizations; o The awardee has the primary responsibility for establishing an internal advisory committee of the collaborating clinical scientists. The committee will have the responsibility for directing and monitoring the progress of the research projects. Beyond this, the committee must develop opportunities for information exchange, seminar presentations, and research training opportunities for students and fellows; o The awardee has the primary responsibility for establishing an external advisory committee of distinguished senior clinical scientists. Annually, the committee will assess the productivity of the CCRE, make recommendations for the future direction of the CCRE initiative, and provide advice and guidance about personnel matters and the allocation of resources to individual projects and investigators; o The awardee will retain custody of and primary rights to the data and intellectual property developed under the award, subject to current government policies regarding rights of access as consistent with current DHHS, PHS, and NIH policies. The NCRR reserves the right to negotiate additional awardee terms and conditions based on recommendations from the Initial Review Group and the National Advisory Research Resources Council. 2. NCRR-DRI Staff Responsibilities The NCRR-DRI will have substantial scientific/programmatic involvement during the award performance period by contributing to planning and assessment activities, providing technical assistance, advice and coordination beyond normal program stewardship for grants. (See INQUIRIES, below.) o The NCRR-DRI will have primary responsibility for stewardship of the award and overall responsibility for monitoring the conduct, progress, and fiscal management of the research program. The NCRR-DRI will provide advice and guidance as appropriate; o The NCRR-DRI will help shape a comprehensive framework for the development of the CCRE and provide technical advice and expertise regarding scientific direction and program management. The NCRR-DRI will provide advice and guidance as appropriate; o The NCRR-DRI will help the applicant institution and CCRE Director establish reasonable time lines to achieve the developmental goals of the CCRE. The NCRR- DRI will facilitate interactions between the awardee and collaborating investigators. The NCRR-DRI will use programmatic authority within the Research Centers in Minority Institutions (RCMI) Program to assist in the sharing of research resources and infrastructure for CCRE awards at RCMI-supported institutions; o The NCRR-DRI will reserve the authority to recommend reductions in budget, withhold support, or suspend and/or terminate the award if technical performance falls below acceptable standards for quality and timeliness; o The NCRR-DRI will actively participate as a non-voting member in all meetings of the external advisory committee during the performance period of the award; o The NCRR-DRI will have the authority to recommend additional research endeavors within the approved research and negotiated budgets; o The NCRR-DRI reserves the right to include selected extramural and intramural staff as consultants/experts on scientific issues during the performance period of the award. 3. Arbitration Any disagreements about scientific/programmatic matters (within the scope of the award) between the awardee and NCRR may be brought to an arbitration panel convened by the Director, NCRR. The arbitration panel will be composed of three members, one person selected by the awardee, one person selected by the NCRR, and a third person selected by these two members. The decision of the arbitration panel, by majority vote, will be binding. The process to resolve programmatic differences described above in no way affects the rights of a recipient of a cooperative agreement assistance grant to appeal an adverse determination in accordance with PHS regulations at 42 CFR Part 50, Subpart D, and DHHS regulations at 45 CFR Part 16. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH-supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. Adequate plans to include both genders and minorities and their subgroups as appropriate for the scientific goals of the research must be included. Plans for recruitment and retention of subjects will be evaluated. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing research involving human subjects should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research," which was published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. This information is available on the Internet at https://grants.nih.gov/grants/guide/notice-files/not94-105.html. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of NIH that children (i.e., individuals under the age of 21) must be included in all human subjects research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them. This applies to all initial (Type 1) applications submitted for receipt dates after October 1, 1998. All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects" that was published in the NIH Guide for Grants and Contracts, March 6, 1998, and is available at the following URL address: https://grants.nih.gov/grants/guide/notice-files/not98-024.html APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 4/98) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910; telephone (301) 710-0267; Email: GrantsInfo@nih.gov; and from the NIH program administrator listed under INQUIRIES. An application for a CCRE award must include the following: o A research plan for up to five years that includes the proposed organization and component functions of the CCRE. The plan should demonstrate the applicant's knowledge, ingenuity and commitment to developing productive, competitive clinical research; o A description of and justification for the proposed individual research projects (15 page limitation for the Research Plan Section for each project). Applicants are required to propose up to three meritorious research projects. Competitive applications will develop new and/or strengthen existing collaborative projects with NIH/PHS grantees from research-intensive institutions. Applicants must clearly define the nature and extent of the research collaboration, such that the necessary fiscal and scientific aspects are fully explained in the application; o A description of the research and research training goals and capabilities of the proposed CCRE. The Program Director and the DRI must establish a time line for supported applicant investigators to prepare and submit proposals for traditional research grant review during the performance period of the CCRE award; and, o A description of the infrastructure for conducting studies aimed a developing a competitive clinical research program. The CCRE application must address the following key elements: 1. Administration o Define the chain of responsibility for decision making and administration, beginning at the level of the institution's President and including all key staff (e.g., Sponsored Programs Administrator, Department Chair, and Dean). Describe the plans for day-to-day administration of the CCRE, including program coordination, planning, and evaluation. Describe the proposed relationship of the CCRE to the RCRII or other clinical research activities and, in detail, how the CCRE initiative will augment and strengthen the existing clinical research infrastructure; o The applicant must identify and outline plans for support staff (e.g., grants management, administrative, and technical) to ensure the timely ordering of research supplies, equipment, and other resources essential to the scientific productivity of the research award. If these resources are provided via an existing RCRII award, they must not be requested in this application. 2. Program Direction/Advisory Committee o Selection and appointment of a CCRE Program Director who has had experience with clinical research funding and research training; o Appointment of an Advisory Committee whose composition consists of clinical investigators whose research experience and expertise compliments the research focus of the CCRE; o A research plan for up to five years that includes the proposed organization and component functions of the CCRE. The plan should demonstrate the applicant's knowledge, ingenuity, practicality, and commitment to developing a significant, productive, research program, and describe how the proposed activities will enhance the scientific capabilities of faculty and fellows involved in clinical research; o Establishment of a time-line by the Program Director for developmental project investigators to prepare and submit proposals for traditional research grant review during the performance period of the CCRE award. 3. Institutional Commitment/Supporting Infrastructure o Evidence that the senior leadership at the applicant institution has addressed issues such as tenure, promotion, research release-time, and other personnel matters pertaining to the scientific success of the CCRE; o A research plan for up to five years that includes the proposed organization and component functions of the CCRE. The plan should demonstrate the institution's commitment to developing a significant, productive, research program; o Documentation/evidence of institutional commitment and the availability of technical resources and facilities for the long-term support of the CCRE. Features of the institutional environment that are relevant to effective accomplishment of the CCRE overall goals must be briefly described; o As appropriate, availability of existing resources (e.g., clinical and laboratory facilities, patient populations, geographic distributions of space and personnel) and collaborative resources should be described; o A letter of support from a senior institution official (e.g., President or Dean) should outline the commitment for resources and facilities to sustain and support the CCRE throughout the period of funding and beyond the performance period of this award; o The applicant institution must show evidence of an existing research infrastructure that can support clinical research. Previous (past five years) and current research support used for clinical research should be described. The existing research infrastructure and needed enhancements must be delineated. 4) Collaboration o Competitive applications may include no more than three developmental clinical research projects. Each project must have a PHS-supported grantee at a near-by research-intensive institution as a collaborator. Investigators must clearly define the nature and extent of the research collaboration, such that they fully explain the necessary administrative, fiscal, and scientific aspects in the application; o The nature and scope of the collaborative research projects must be documented. Collaborating investigators must devote a minimum of 20 percent research effort to the respective projects. These costs may be paid via a subcontract. 5) Developmental Projects o A description of and justification for the developmental research projects and core service facilities. Applicants are required to propose up to three meritorious research projects, and must describe the nature and scope of any scientific research collaborations; o Selection of up to three highly qualified investigators from the applicant organization to propose and direct meritorious research projects suited to their research expertise. These projects should focus on one of the diseases that disproportionately affect the health status of minority populations (see above). These investigators are required to devote a minimum of 50 percent research effort to their respective projects; o Each project must be presented in the format of an R01 application. The research plan should be limited to 15 pages for Research Plan Section (a-d in the PHS 398). The maximum allowable direct cost is $200,000 per year/project. These projects must involve clinical investigators at nearby institutions as collaborators. The RFA label, available in the PHS 398 application kit, must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA number and title must be typed on line 2 of the face page of the application form and the "YES" box must be marked. Submit a signed, typewritten original of the application, including the Checklist, and three signed photocopies, in one package to: CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for express/courier service) At the time of submission, two additional copies of the application must be sent to: Dr. Grace S. Ault Office of Review National Center for Research Resources 6705 Rockledge Drive, Room 6018 - MSC 7965 Bethesda, MD 20892-7965 Bethesda, MD 20817 (for express/courier service) Telephone: (301) 435-0811 FAX: (301) 480-3660 Email: GraceA@ncrr.nih.gov Schedule Application Receipt Date: March 11, 1999 Council Review: September 7-8, 1999 Earliest Award Date: September 30, 1999 Applications must be received by March 11, 1999. If an application is received after that date, it will be returned to the applicant without review. The Center for Scientific Review (CSR) will not accept an application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed for completeness by CSR and responsiveness by NCRR staff. Applications that are incomplete, non-responsive to this RFA, and/or exceed the maximum first year total direct cost limit of $1 million, excluding indirect costs for consortium budgets, will be returned to the applicant without further consideration. The applications will be reviewed by an NCRR Special Emphasis Panel. The NCRR will withdraw from further competition those applications judged by the review committee to be noncompetitive for an award and notify the applicant Principal Investigator and applicant organization. The review of a CCRE application will be based on the feasibility and potential for the proposed Center to create an environment for clinical investigation, the recruitment of magnet clinical investigators conducting clinical research on diseases that have disproportionate effect on minority populations, the proposed Program Director, the institutional support and infrastructure, the quality of the clinical research projects and collaborations, and the potential of young clinical investigators to gain scientific independence. REVIEW CRITERIA The review will be organized according to the following considerations: 1. Administration o The chain of command in the administration of the grant and the Center; o The day-to-day administration of the Center, coordination of research activities, planning and evaluation; o The plans for the establishment and utilization of support structure (grants management, administrative, technical) to provide resources essential to carry out the scientific projects; o The relationship of the proposed program to the already existing RCRII, if applicable. 2. Program Direction/Advisory Committee o The qualifications and track record of the proposed CCRE Program Director; his/her experience, publication record in clinical research as a funded clinical investigator; previous experience as mentor of young investigators and serving as role model; and the administrative qualifications to direct the Center; o Selection and appointment of members of the Advisory Committee; the proposed oversight role of the Advisory Committee in the functioning of the Center; o The Program Director's knowledge, commitment and ingenuity to develop a productive research program as reflected in the five-year research plan. 3. Institutional Commitment/Supporting Infrastructure o Documentation of institutional endorsement of the proposed five-year plan, including a letter of support from a senior institutional official; features of the institutional environment that are relevant or unique in assuring the success of the program; o Existing research infrastructure (laboratory space, equipment, clinical facilities, animal housing, computer resources) and its commitment to the proposed CCRE program that would facilitate and support the proposed clinical research; o Justification for the proposed needed infrastructure enhancement; o Availability of patient population and patient recruitment. 4. Overall Program Quality o Past and current clinical research support, including institutional grant support for clinical research; o Recruitment of senior clinical investigators that would allow the development of clinical research on diseases that have disproportionate affect on minority populations; o The potential for enriching the academic and intellectual milieu for doing clinical research and the feasibility and potential for junior investigators to gain scientific independence under the mentorship of senior clinical investigators; o The proposed five year plan and the establishment of the developmental project for young investigators and fellows; plans to prepare young investigators to write their own grant proposal and become independent investigators. 5. Collaboration o The strength of the relationship of the applicant investigators and collaborating researchers, if any, particularly the academic qualifications, research experience, expertise and research productivity, as well as administrative and fiscal relationships; o The importance and relevance of each collaborative project to the achievement of CCRE program objectives. 6. Developmental Projects Each of the Developmental Projects will be evaluated for its scientific merits using the standard NIH R01 review criteria: (1) Significance: Does this protocol address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field? (2) Approach: Are the conceptual framework, design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the protocol? Does the applicant acknowledge potential problem areas and consider alternative tactics? (3) Innovation: Does the protocol employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies? (4) Investigator: Is the investigator appropriately trained and well suited to carry out this protocol? Is the work proposed appropriate to the experience level of the Principal Investigator and other researchers (if any)? (5) Environment: Does the scientific environment in which the protocol will be performed contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support? A protocol does not need to be strong in all categories to be judged likely to have a major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work, that by its nature is not innovative, but is essential to move a field forward. In addition to the above criteria, in accordance with NIH policy, all applications will also be reviewed with respect to the following: o The adequacy of plans to include both genders, minorities and their subgroups, and children as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated; o The adequacy of the proposed protection for humans (including biohazards safety in the research environment), animals, or the environment, to the extent that they may be adversely affected by the project(s) proposed in the application; o The reasonableness and appropriateness of the proposed budget and duration, including the justification for requested personnel, equipment and other items, in relation to the aims and methods of the proposed research studies. AWARD CRITERIA Funding decisions will be based on scientific and technical merit as determined by a Special Emphasis Panel and the National Advisory Research Resources Council, program balance, and the availability of funds. INQUIRIES Inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Dr. Sidney A. McNairy, Jr. Research Infrastructure National Center for Research Resources 6705 Rockledge Drive - MSC 7965 Bethesda, MD 20892-7965 Telephone: (301) 435-0788 FAX: (301) 480-3770 Email: SidneyM@ncrr.nih.gov For information on budget and fiscal matters, contact: Mr. Paul Karadbil Office of Grants Management National Center for Research Resources 6705 Rockledge Drive - MSC 7965 Bethesda, MD 20892-7965 Telephone: (301) 435-0844 FAX: (301) 480-7777 Email: PaulK@ncrr.nih.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.389 (Research Infrastructure). Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulation 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Return to NIH Guide Main Index
![]() |
Office of Extramural Research (OER) |
![]() |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
![]() |
Department of Health and Human Services (HHS) |
![]() |
||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |